14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026
WEST vs BHST: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
WEST Wins Head-to-Head Institutional Verdict (4–2 across 6 Pillars · 6–2 Matrix Metrics)
WEST Overall Winner
6-Pillar Tally: WEST 4 – 2 BHST
Matrix Metrics: WEST 6 – 2 BHST
As of Nov 20, 2026, Westrock Coffee Company (WEST) is the stronger overall head-to-head candidate over BioHarvest Sciences Inc. (BHST) in the Tradestie Institutional Equity Comparison Engine, winning 6–2 core matrix metrics and 4–2 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). WEST carries a Unified Composite Score of 44.7/100 (HOLD) at $7.22 (N/M Forward P/E, -1.2% operating margin), whereas BHST carries 58.2/100 (HOLD) at $1.30 (N/M Forward P/E, -18.0% operating margin).
Composite vs. Pillar Nuance: While BHST currently prints a higher short-term Unified Composite Score (58.2/100 HOLD vs. WEST 44.7/100 HOLD), WEST captures the overall institutional head-to-head verdict (6–2 matrix metrics and 4–2 across the 6 pillars) due to superior fundamental profitability (-1.2% vs. -18.0% operating margin) and revenue trajectory (-15.4% vs. +3.8% YoY).
Technical & Structure Timing Caution: WEST trades in a Neutral technical trend (CONSOLIDATION options phase, RSI 29.2); meanwhile BHST is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 37.2). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Competes within the Packaged Foods value chain with $29.9M market capitalization and -18.0% operating margin.
OpEx & R&D Reinvestment77.0% of Rev ($27M)
90D Engineering Disclosures0 Published
Investor FAQ WEST vs BHST Key Questions & Quantitative Answers
As of Nov 20, 2026, Westrock Coffee Company (WEST) is the stronger overall head-to-head candidate over BioHarvest Sciences Inc. (BHST) in the Tradestie Institutional Equity Comparison Engine, winning 6–2 core matrix metrics and 4–2 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). WEST carries a Unified Composite Score of 44.7/100 (HOLD) at $7.22 (N/M Forward P/E, -1.2% operating margin), whereas BHST carries 58.2/100 (HOLD) at $1.30 (N/M Forward P/E, -18.0% operating margin). Composite vs. Pillar Nuance: While BHST currently prints a higher short-term Unified Composite Score (58.2/100 HOLD vs. WEST 44.7/100 HOLD), WEST captures the overall institutional head-to-head verdict (6–2 matrix metrics and 4–2 across the 6 pillars) due to superior fundamental profitability (-1.2% vs. -18.0% operating margin) and revenue trajectory (-15.4% vs. +3.8% YoY). Technical & Structure Timing Caution: WEST trades in a Neutral technical trend (CONSOLIDATION options phase, RSI 29.2); meanwhile BHST is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 37.2). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
WEST leads the Growth & Scale pillar: WEST posts -15.4% YoY revenue growth and +0.0% YoY earnings growth on $1.25B TTM revenue (10.9% gross margin, -1.2% operating margin), compared with BHST at +3.8% YoY revenue growth and +0.0% YoY earnings growth on $35M TTM revenue (59.0% gross margin, -18.0% operating margin). Across the 6-period historical trajectory (FY2020 to FY2025), WEST cumulative revenue shifted +116.4% while BHST shifted +200.0%. In operating R&D and SG&A reinvestment, WEST deploys 12.1% of Rev ($152M) (0 90-day corporate R&D disclosures) versus 77.0% of Rev ($27M) (0 disclosures) for BHST.
BHST screens cheaper on headline valuation multiples. WEST trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 1.0x EV/Revenue (2.4% FCF margin), whereas BHST trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 0.7x EV/Revenue (-26.6% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against WEST (-20.9% ROE) versus BHST (-142.5% ROE) capital efficiency.
In options market volatility and institutional positioning, WEST carries 48.8% implied volatility (5th %ile, Compressed (<25th %ile)), a 3.87x (Put-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a CONSOLIDATION options structure phase (0.56β · 69% Vol realized risk). By comparison, BHST carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.25β · 86% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.